Education
About Us
Working with TipRanks
Follow Us
CanSino Biologics, Inc. Class H (HK:6185)
:6185
6185 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$16.34 - HK$42.20
Previous CloseN/A
Volume470.05K
Average Volume (3M)1.59M
Market Cap
HK$9.49B
Enterprise ValueHK$6.53B
Total Cash (Recent Filing)-¥197.38M
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Apr 29, 2025EPS Estimate
>-0.01Last Dividend Ex-Date
Jul 13, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)-1.66
Shares Outstanding132,670,900
10 Day Avg. Volume2,070,842
30 Day Avg. Volume1,593,126
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.42
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
CanSino Biologics, Inc. Class H News
PremiumCompany Announcements
CanSino Biologics to Review Q1 2025 Results in Upcoming Board Meeting
PremiumCompany Announcements
CanSino Biologics Releases 2024 Annual ResultsPremiumCompany Announcements
CanSino Biologics to Announce 2024 Annual Results and Dividend Consideration
PremiumCompany Announcements
CanSino Biologics Reports 137% Revenue Increase Amid Reduced Losses in 2024
PremiumCompany Announcements
CanSino Biologics’ DTcP Infant Vaccine Receives Priority Review Status
PremiumCompany Announcements
CanSino Biologics Forecasts Improved Financial Performance in 2024---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
2.83%
Mutual Funds
― Other Institutional Investors
94.42% Public Companies and
Individual Investors
6185 FAQ
What was CanSino Biologics, Inc. Class H’s price range in the past 12 months?
CanSino Biologics, Inc. Class H lowest stock price was HK$16.34 and its highest was HK$42.20 in the past 12 months.
What is CanSino Biologics, Inc. Class H’s market cap?
CanSino Biologics, Inc. Class H’s market cap is HK$9.49B.
When is CanSino Biologics, Inc. Class H’s upcoming earnings report date?
CanSino Biologics, Inc. Class H’s upcoming earnings report date is Apr 29, 2025 which is in 5 days.
How were CanSino Biologics, Inc. Class H’s earnings last quarter?
CanSino Biologics, Inc. Class H released its earnings results on Mar 25, 2025. The company reported -HK$0.671 earnings per share for the quarter, missing the consensus estimate of -HK$0.648 by -HK$0.022.
Is CanSino Biologics, Inc. Class H overvalued?
According to Wall Street analysts CanSino Biologics, Inc. Class H’s price is currently Overvalued.
Does CanSino Biologics, Inc. Class H pay dividends?
CanSino Biologics, Inc. Class H pays a Notavailable dividend of HK$0.937 which represents an annual dividend yield of N/A. See more information on CanSino Biologics, Inc. Class H dividends here
What is CanSino Biologics, Inc. Class H’s EPS estimate?
CanSino Biologics, Inc. Class H’s EPS estimate is >-0.01.
How many shares outstanding does CanSino Biologics, Inc. Class H have?
CanSino Biologics, Inc. Class H has 132,670,900 shares outstanding.
What happened to CanSino Biologics, Inc. Class H’s price movement after its last earnings report?
CanSino Biologics, Inc. Class H reported an EPS of -HK$0.671 in its last earnings report, missing expectations of -HK$0.648. Following the earnings report the stock price went down -3.202%.
Which hedge fund is a major shareholder of CanSino Biologics, Inc. Class H?
Currently, no hedge funds are holding shares in HK:6185
---
CanSino Biologics, Inc. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
75.42%
12-Months-Change
Fundamentals
Return on Equity
-7.45%
Trailing 12-Months
Asset Growth
-17.85%
Trailing 12-Months
Company Description
CanSino Biologics, Inc. Class H
CanSino Biologics, Inc. Class H (6185) is a Chinese biopharmaceutical company that specializes in the research, development, manufacturing, and commercialization of vaccines. The company focuses on the development of innovative vaccines for a variety of infectious diseases. Its core products include vaccines against COVID-19, meningitis, and other prevalent diseases. CanSino Biologics is recognized for its expertise in vaccine development and its contributions to public health.
---
6185 Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering 6185
1 Year
Unknown AnalystUBS
Not Ranked
1 Year Success Rate
0/0 ratings generated profit
1 Year Average Return
0.00%
reiterated a buy rating a year ago
Copying Unknown Analyst's trades and holding each position for 1 Year would result in - of your transactions generating a profit, with an average return of 0.00% per trade.
---